FDA approves a second Alzheimer's drug that can modestly slow disease
A new Alzheimer's drug approved by U.S. officials can modestly slow the disease, offering a new option for early-stage patients.
FDA Approves Second Alzheimer's Drug That Can Modestly Slow Disease
FDA approved Kisunla, a new Alzheimer's drug that slows cognitive decline modestly for early-stage patients.
New Drug Approved for Early Alzheimer's
The FDA approved a new drug for Alzheimer's disease, Donanemab (Kisunla), shown to slow cognitive decline in early stages with significant safety risks.
FDA approves a second Alzheimer's drug that can modestly slow disease
A new Alzheimer's drug approved by U.S. officials can modestly slow the disease, offering a new option for early-stage patients.
FDA Approves Second Alzheimer's Drug That Can Modestly Slow Disease
FDA approved Kisunla, a new Alzheimer's drug that slows cognitive decline modestly for early-stage patients.
New Drug Approved for Early Alzheimer's
The FDA approved a new drug for Alzheimer's disease, Donanemab (Kisunla), shown to slow cognitive decline in early stages with significant safety risks.